-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide.
Colorectal cancer blood vessels
Regorafenib is a small molecule tyrosine kinase inhibitor.
Regorafenib is a small molecule tyrosine kinase inhibitor.
immunity
This study is a single-arm, multi-center phase II trial.
PFS and OS in microsatellite-stabilized patients treated with regorafenib + orvizumab
PFS and OS in microsatellite-stabilized patients treated with regorafenib + orvizumabA total of 48 patients were recruited from 4 centers, and 43 of them could be evaluated for efficacy.
The best response is to maintain a stable condition, seen in 23 (53.
The prediction of tumor infiltration of CD163+ macrophages on the prognosis of patients
The prediction of tumor infiltration of CD163+ macrophages on the prognosis of patientsHigh baseline infiltration of tumor-associated macrophages was significantly associated with poor PFS (1.
High baseline infiltration of tumor-associated macrophages was significantly associated with poor PFS (1.
In short, mAb Orville Ruige Fini joint portion can be mobilized anti microsatellite stable patients with colorectal cancer tumor immunity force.
Original source:
Sophie Cousin, et al.
aacrjournals.
org/content/27/8/2139" target="_blank" rel="noopener">Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
Leave a message here